Introduction
============

Diabetic neuropathy (DN) is a very common, symptomatic, long-term complication of diabetes mellitus, affecting nearly 50% of patients with type 1 and/or type 2 diabetes.[@b1-dddt-12-2827] According to International Diabetes Federation data, \~592 million people worldwide will be diagnosed with diabetes by 2035.[@b2-dddt-12-2827] DPN affectŝ236 million people, primarily in low- and middle-income countries, causing a very large financial burden.[@b3-dddt-12-2827],[@b4-dddt-12-2827] Diabetic peripheral neuropathy (DPN) is closely associated with high morbidity, mortality, and diminished quality of life.[@b5-dddt-12-2827] Diabetic damage due to hyperglycemia and metabolic imbalance -- primarily, oxidative stress -- may appear in the neurons (axons or myelin sheaths) of DPN patients.[@b6-dddt-12-2827] Therefore, the typical clinical manifestations of DPN are tingling, burning, pain, cramps, paresthesia, and numbness.[@b3-dddt-12-2827] With regard to oxidative stress and the related pathways, some drugs, such as alpha lipoic acid, aldose reductase inhibitors (ARIs; eg, epalrestat), and protein kinase C inhibitors, are being investigated.[@b6-dddt-12-2827] These drugs have been widely used to treat DPN in clinical or intensive long-term comparative trials.

Nerve conduction velocity (NCV) is an objective indicator of neuronal damage in the distal segment of the peripheral nerves and is accepted as an essential part of the diagnosis of DPN.[@b7-dddt-12-2827]--[@b9-dddt-12-2827] Previous studies have shown that motor nerve conduction velocity (MNCV) or sensory nerve conduction velocity (SNCV) are significantly reduced with the development of DPN.[@b10-dddt-12-2827],[@b11-dddt-12-2827] ALA -- a coenzyme in the tricarboxylic acid cycle -- is an antioxidant that may prevent and reduce diabetic micro- and macrovascular complications[@b12-dddt-12-2827] and is an effective treatment of DPN.[@b13-dddt-12-2827] Experimental studies have proved that ALA can improve nerve blood flow, reduce oxidative stress, and improve distal nerve conduction.[@b14-dddt-12-2827] One meta-analysis reported that infusions of ALA (600 mg IV/day) ameliorated the symptoms of neuropathy after 3 weeks,[@b15-dddt-12-2827] with IV therapy being more effective than oral treatment (SMD =−2.8 vs SMD =−1.8).[@b16-dddt-12-2827] Epalrestat is an ARI that relieves oxidative stress and suppresses the polyol pathway, which delays the progression of DPN and effectively and safely improves both DN symptoms and the MNCV in the context of neuropathy.[@b17-dddt-12-2827]--[@b19-dddt-12-2827]

Accumulating evidence has shown that ALA combined with epalrestat may be a viable option for patients with DPN because of its marked beneficial effect on clinical symptoms and nerve conduction velocity (NCV).[@b20-dddt-12-2827] However, the available randomized controlled trials (RCTs) examining this combination therapy have not been systematically retrieved and evaluated. We conducted a meta-analysis to assess the efficacy and safety of ALA combined with epalrestat for patients with DPN.

Materials and methods
=====================

This systematic review was registered in PROSPERO CRD42017081310, and we strictly followed the Cochrane Collaboration framework guidelines[@b21-dddt-12-2827] and the PRISMA Statement[@b22-dddt-12-2827] to conduct the review ([Table S2](#SD2-dddt-12-2827){ref-type="supplementary-material"}).

Selection criteria
------------------

Studies that satisfied the following criteria were selected. 1) Patients: Patients with DPN. The diagnostic criteria for diabetes mellitus and its complications in the trials were in accordance with the criteria of the 1999 World Health Organization (WHO) guideline.[@b23-dddt-12-2827] The diagnostic criteria for DPN were in accordance with a statement by the American Diabetes Association[@b24-dddt-12-2827] or the guidelines for the prevention and treatment of Type 2 diabetes (2013 version) of the Chinese Diabetes Society.[@b25-dddt-12-2827] Patients with other types of peripheral neuropathy, such as cerebral infarction, Guillain--Barre syndrome, severe venovascular disease, cervical spondylosis, and lumbar lesions, were excluded. There were no restrictions on patient race, region, age, sex, or on the severity or duration of DPN. 2) Interventions: Combined treatment was compared to epalrestat monotherapy or on the basis of co-intervention for the treatment of DPN patients. 3) Comparisons: Subjects received ALA combined with epalrestat vs epalrestat alone. 4) Outcomes: Clinical effectiveness rate, Toronto Clinical Scoring System (TCSS), Total Symptom Score (TSS), adverse reactions, MNCV, and SNCV were measured. The total effectiveness rate was calculated on the basis of following criteria: subjective symptom alleviated, tendon reflex improved, and NCV increased by ≥3 m/s after treatment. 5) Study design: RCTs that determined the clinical utility of ALA combined with epalrestat for the treatment of DPN were selected. Reviews, cross-sectional studies, cohort studies, animal experiments, and commentaries were excluded.

Search strategy
---------------

A systematic literature search of multiple databases for relevant trials was undertaken. All Chinese databases, including the Chinese Biomedical Database, Wanfang Data, the VIP Chinese Science and Technology Journals Database, the China National Knowledge Infrastructure, as well as English databases, such as PubMed and Cochrane Library, were searched from their inception to October 31, 2017. For the Chinese databases, free-text terms such as "epalrestat" or "lipoic acid" and "diabetic peripheral neuropathy" or "peripheral neuropathy" or "diabetic neuropathy" or "DPN" and "randomized controlled trial" or "randomized" and "blind" were used; there were no restrictions on subheadings. For the English databases, the following mesh terms were used, with no restriction on subheadings: ((diabetic AND peripheral neuropathy) OR (diabetic neuropathy OR diabetic peripheral neuropathy)) AND ((thioctic acid) OR (thioctic AND acid) OR (lipoic acid) OR (lipoic AND acid)) AND (epalrestat) AND (randomized OR randomized controlled trial) AND blind. The search strategies of PubMed and CNKI were showed in [Table S1](#SD1-dddt-12-2827){ref-type="supplementary-material"}. Other electronic databases will be search using the similar strategy. Publication languages were confined to Chinese and English. Clinical trials published in abstract form were selected only if sufficient data could be retrieved from the abstract or authors. The reference lists of the potentially eligible studies were also reviewed to discover additional clinical trials missed by the initial search.

Data selection
--------------

All retrieved results were imported into NoteExpress 3.2.0. Duplicate data from different databases were identified by NoteExpress 3.2.0, and two reviewers (Wang XT and Lin HX) independently screened the remaining abstracts and full texts of potentially eligible trials. Any disagreements were settled by discussion among four authors (Wang XT, Lin HX, Jin YL and Zhang R). SX checked the final data set. Treatment strategies that were not repeated were eliminated.

Data extraction and risk of bias
--------------------------------

For each eligible study, two reviewers (Wang XT and Lin HX) extracted study information (first author names, publication year), patient data (age, sample sizes of the treatment group and control group), therapeutic strategy (intervention methods, intervention time), and DPN outcome. Risk assessment and quality evaluation, as determined by the Cochrane criteria, were used to evaluate each eligible study.[@b26-dddt-12-2827]

Statistical analysis
--------------------

The clinical effectiveness rate, TCSS, TSS, adverse reactions, MNCV, and SNCV were evaluated and merged. Review Manager (version 5.3.0) software was utilized to analyze the data. The data are presented as RR or weighted mean difference (WMD) and 95% CI for the included studies. Statistical heterogeneity was assessed using the Chi-squared test and *I*^2^ values.[@b27-dddt-12-2827] *I*^2^\>75% indicated significant heterogeneity, 50%, *I*^2^≤75% was regarded as mildly significant heterogeneity, and 0% ≤ *I*^2^≤50% was defined as indicating no heterogeneity. A random-effects model and sensitivity analysis was undertaken when mild or significant heterogeneity (*P*\<0.05, *I*^2^\>50%) was detected among the analyzed studies. Moreover, subgroup analysis was conducted on the basis of different therapeutic methods or follow-up durations. A fixed-effects model was used in the absence of heterogeneity. When possible, comparisons of studies that used the same treatment strategy for different durations were made using the chi-squared test and the associated *P*-value. Funnel plots, Begg's test, and Egger's test were conducted on clinical outcomes to further analyze the potential publication bias. Begg's test *P*\>0.05 and Egger's test *P*\>0.05 indicated no significant publication bias.

Results
=======

Eligible studies
----------------

Our initial search strategy yielded 240 potential articles, and [Figure 1](#f1-dddt-12-2827){ref-type="fig"} shows the search process. Duplicate records were removed in NoteExpress 3.2.0 (n=135), and 59 studies were excluded after screening of the titles and abstracts. The full text of 46 studies was screened. Twenty-eight trials using other drugs, three trials with suspected duplicated data, and three trials[@b28-dddt-12-2827]--[@b30-dddt-12-2827] that did not use the same treatment strategy were removed. Twelve clinical trials were included in the meta-analysis. The detailed characteristics of the included studies are presented in [Table 1](#t1-dddt-12-2827){ref-type="table"}.

Risk of bias of the included studies
------------------------------------

The quality of the included studies was high in terms of randomization, completeness of outcome data, selective reporting, and other potential biases. However, the studies conducted by Fang[@b32-dddt-12-2827] and Huang[@b41-dddt-12-2827] did not mention a randomized design. In addition, the poor allocation concealment, inadequate blinding of participants or personnel, and inadequate blinding of outcome assessment should be considered ([Figure 2](#f2-dddt-12-2827){ref-type="fig"}).

Total effectiveness rate
------------------------

Eight studies containing total effectiveness rate data were included. The meta-analysis was conducted using a fixed-effects model based on the lack of heterogeneity (*I*^2^=0%, *P*\>0.05). According to the subgroup analysis, although the total effectiveness rate differed by treatment strategy, the combined treatment exhibited a better total effectiveness rate than epalrestat alone (ALA 600 mg/d qd combined with epalrestat 50 mg tid for 14 days -- RR: 1.40, 95% CI: 1.16--1.69, *P*=0.0005; for 28 days -- RR: 1.48, 95% CI: 1.27--1.72, *P*\<0.00001; ALA 300 mg/d qd combined with epalrestat 50 mg tid for 28 days -- RR: 1.37, 95% CI: 1.18--1.59, *P*\<0.0001; [Figure 3](#f3-dddt-12-2827){ref-type="fig"}).

Median MNCV
-----------

Ten trials investigated the median MNCV. A beneficial and statistically significant effect of combined treatment on median MNCV was observed in two different treatment strategies compared with epalrestat monotherapy. The pooled results of ALA 600 mg/d qd combined with epalrestat 50 mg tid were significantly higher than that of epalrestat monotherapy (14 days -- pooled WMD: 7.98, 95% CI: 6.17--9.80, *P*\<0.00001; 21 days -- WMD: 2.74, 95% CI: 1.50--3.98, *P*\<0.0001; 28 days -- WMD: 9.01, 95% CI: 3.46--14.56, *P*=0.001). Significant differences were identified between these different treatment durations (*χ*^2^=24.41, *P*\<0.00001). Moreover, ALA 300 mg/d qd combined with 50 mg tid epalrestat for 28 days indicated the benefit of the combined-treatment regimen (WMD: 6.12, 95% CI: 5.04--7.20, *P*\<0.00001; [Table 2](#t2-dddt-12-2827){ref-type="table"}).

Peroneal MNCV
-------------

Eleven trials investigated peroneal MNCV. The pooled results suggested a significant difference in peroneal MNCV between the combined treatment and epalrestat-alone groups in two different treatment strategies (ALA 600 mg/d qd combined with epalrestat 50 mg tid: for 14 days -- WMD: 9.77, 95% CI: 7.78--11.75, *P*\<0.00001; for 21 days -- WMD: 4.18, 95% CI: 1.49--6.88, *P*=0.002; for 28 days -- WMD: 7.13, 95% CI: 3.94--10.32, *P*\<0.0001. ALA 300 mg/d qd combined with epalrestat 50 mg tid for 28 days -- WMD: 6.68, 95% CI: 5.82--7.55, *P*\<0.00001; [Table 2](#t2-dddt-12-2827){ref-type="table"}). There were significant differences between the results obtained using ALA 600 mg/d qd combined with epalrestat 50 mg tid for different durations (*χ*^2^=10.84, *P*=0.004).

Median SNCV
-----------

Ten studies provided median SNCV data of patients with DPN. The analysis revealed a significant improvement in median SNCV in combined-treatment patients compared to epalrestat-treated patients in two different treatment strategies (ALA 600 mg/d qd combined with epalrestat 50 mg tid: for 14 days -- WMD: 7.12, 95% CI: 5.13--9.11, *P*\<0.00001; for 21 days -- WMD: 3.88, 95% CI: 3.08--4.68, *P*\<0.00001; for 28 days -- WMD: 9.97, 95% CI: 1.56--18.38, *P*=0.02. ALA 300 mg/d qd combined with epalrestat 50 mg tid for 28 days -- pooled WMD 6.70, 95% CI: 5.75--7.65, *P*\<0.00001; [Table 2](#t2-dddt-12-2827){ref-type="table"}). There were significant differences between the results obtained using ALA 600 mg/d qd combined with epalrestat 50 mg tid for different periods of time (*χ*^2^=10.51, *P*=0.005).

Peroneal SNCV
-------------

Eleven trials were included for a comparison of peroneal SNCV results. The pooled results indicated that ALA combined with epalrestat significantly improved peroneal SNCV in different treatment strategies (ALA 600 mg/d qd combined with epalrestat 50 mg tid: for 14 days -- WMD: 7.76, 95% CI: 5.77--9.76, *P*\<0.00001; for 21 days -- WMD: 3.30, 95% CI: 0.45--6.14, *P*=0.02; for 28 days -- WMD: 6.29, 95% CI: 3.01--9.58, *P*=0.0002. ALA 300 mg/d qd combined with epalrestat 50 mg tid for 28 days -- WMD: 4.27, 95% CI: 3.34--5.20, *P*\<0.00001; [Table 2](#t2-dddt-12-2827){ref-type="table"}). There were significant differences between the results obtained using ALA 600 mg/d qd combined with epalrestat 50 mg tid for different periods of time (*χ*^2^=6.34, *P*=0.04).

TCSS
----

Three trials of 188 patients were included in the TCSS data. A random-effects model was developed because of the high heterogeneity (*I*^2^=80%, *P*=0.006). The combined WMD was −1.60 (95% CI: −2.91, −0.29; *P*=0.02), revealing that the TCSS was significantly lower in the group receiving a combination of ALA 600 mg/d qd and epalrestat 50 mg tid than in the group receiving epalrestat monotherapy after 21 days of treatment ([Table 2](#t2-dddt-12-2827){ref-type="table"}).

TSS
---

A fixed-effects model was created because no heterogeneity was found between the three studies (*I*^2^=0%, *P*=0.69). The pooled data demonstrated that TSS was significantly lower in the combination treatment group (ALA 600 mg/d qd and epalrestat 50 mg tid) than in the epalrestat-alone group after 21 days of treatment (WMD: −0.93, 95% CI: −1.27, −0.60, *P*\<0.00001; [Table 2](#t2-dddt-12-2827){ref-type="table"}).

Adverse reactions
-----------------

Only Han's study[@b38-dddt-12-2827] reported an allergic reaction (1/55) in the combined-treatment group. Three trials[@b31-dddt-12-2827],[@b35-dddt-12-2827],[@b40-dddt-12-2827] reported no adverse reactions in either the combination treatment or epalrestat group.

Sensitivity analysis
--------------------

In the sensitivity analysis, the pooled data of the above outcomes did not show significant changes, indicating that the pooled results were steady. With respect to the ALA 600 mg qd combined with epalrestat 50 mg tid for the 28-day subgroup, the observed heterogeneity between therapies for the median MNCV and SNCV was absent after removing the study by Liu[@b33-dddt-12-2827] (*I*^2^=17%, *P*=0.27; *I*^2^=34%, *P*=0.22). In this scenario, based on the results of a fixed-effects model, the combined-treatment regimen dramatically improved the median MNCV and SNCV compared to epalrestat alone (median MNCV: WMD: 6.64, 95% CI: 5.52, 7.36, *P*\<0.00001; median SNCV: WMD: 5.72, 95% CI: 4.98, 6.47, *P*\<0.00001; [Table 3](#t3-dddt-12-2827){ref-type="table"}).

Publication bias
----------------

The funnel plot was essentially symmetrical, indicating no obvious publication bias in the total effectiveness rate. The Begg's test score was *Z*=1.11 (*P*=0.266), and the Egger's test score was *t*=1.31 (*P*=0.238), suggesting no evidence of publication bias ([Figure 4](#f4-dddt-12-2827){ref-type="fig"}).

Discussion
==========

DN includes disorders of peripheral nerves and is a diabetic microvascular complication.[@b6-dddt-12-2827] The prevalence of DPN in patients is approximately 30%, but up to 50% of these patients develop neuropathy during the course of the disease.[@b43-dddt-12-2827] The total annual economic burden associated with DPN and its complications is estimated to be \$4.6--13.7 billion (US), with approximately 27% of the direct medical expense of DM being attributed to DPN.[@b44-dddt-12-2827] The pathogenesis of DPN is not clear; however, defects in metabolic and vascular pathways combined with oxidative stress play important roles in the onset and progression of nerve injury.[@b45-dddt-12-2827] Many potential treatments, such as the curcumin derivative J147 and the methanolic extract of *Juglans regia L*. leaf, are effective in animal models of DPN; however, these treatments have not been validated in clinical trials.[@b46-dddt-12-2827],[@b47-dddt-12-2827] ALA and epalrestat are efficacious in DPN patients and are popular in clinical use.[@b48-dddt-12-2827],[@b49-dddt-12-2827] Many RCTs, especially in recent years, have confirmed that a combination of ALA and epalrestat improves MNCV and SNCV in DPN patients more efficiently than monotherapies.[@b29-dddt-12-2827],[@b33-dddt-12-2827]

In our meta-analysis, 12 studies met our inclusion criteria. The data suggested that combination therapy was superior to epalrestat alone in improving the total effectiveness rate. Furthermore, the combination of ALA plus epalrestat increased the MNCV and SNCV of the median nerve and the nervus peroneus communis compared to epalrestat monotherapy. Notably, combination therapy was better in reducing the TCSS and TSS of patients with DPN. The results of the present meta-analysis are partially consistent with another recent meta-analysis published in September 2015,[@b50-dddt-12-2827] which demonstrated that ALA significantly improved the remission rate of clinical symptoms and nerve conduction velocity. However, combination therapy was not considered in this previous meta-analysis.[@b50-dddt-12-2827] In addition, the Cochrane methodological criteria were not adequately fulfilled, and studies with different intervention times were not included, resulting in lower quality results.[@b50-dddt-12-2827] More clinical trials were published in different databases in recent years, providing us with an opportunity to conduct a higher quality meta-analysis involving trials that considered different ALA doses and durations of intervention.

ALA directly eliminates free radicals, inhibits peroxidation, enhances blood flow, increases nerve Na^+^ −K^+^ ATPase activity, protects endothelial function, and increases the speed of nerve conduction.[@b14-dddt-12-2827],[@b45-dddt-12-2827],[@b51-dddt-12-2827],[@b52-dddt-12-2827] Moreover, these data indicate that ALA benefits the vascular abnormalities of DPN and remarkably improves peripheral nerve function. In addition, ALA increases insulin sensitivity.[@b53-dddt-12-2827] Therefore, ALA is a good option as a treatment for DPN that targets the pathogenic origins of the condition. Epalrestat prevents peripheral nerve injury by reducing expression of antioxidant enzyme and aldose reductase, relieving oxidative stress, and suppressing the overactive polyol pathway.[@b17-dddt-12-2827] Epalrestat is, therefore, a valid choice for DPN treatment. The combination of ALA with epalrestat further improved the symptoms of DPN, NCV, and the peripheral blood levels of high sensitivity C-reactive protein.[@b54-dddt-12-2827] The hospitalization cost study in 58 patients revealed that epalrestat was more economical than other drugs, such as alprostadil, and no difference in the total effectiveness rate was observed for the treatment of DPN for 1 month.[@b55-dddt-12-2827] These data provide a promising option for DPN patients, especially those who have a poor clinical response to epalrestat monotherapy.

Limitations
-----------

There are some limitations of the present meta-analysis. First, most of the included clinical trials in this review were conducted in China, given that few combined-treatment regimens were undertaken outside of China. Data from other countries were not retrieved because of language and database limitations. Treatment strategies that were not repeated were also eliminated, which may have excluded some reliable treatment options. In addition, there were no placebo groups in any of the included trials, making it impossible to eliminate the possibility that the observed responses were due to the placebo effect.

Second, heterogeneity among clinical trials was observed in the analyses of the MNCV and SNCV of the median nerve, specifically for the treatment strategy consisting of ALA 600 mg qd combined with epalrestat 50 mg tid for 28 days. The sensitivity analysis of the pooled data demonstrated that the median MNCV and SNCV were not significantly altered with or without the inclusion of Liu's study,[@b33-dddt-12-2827] indicating that the pooled results were steady. However, a contribution of Liu's study[@b33-dddt-12-2827] to heterogeneity was identified, demonstrating that different doses of ALA and different intervention times may be the sources of heterogeneity.

Third, most of the included clinical trials had relatively poor methodological quality. Fang[@b32-dddt-12-2827] and Huang[@b41-dddt-12-2827] did not mention details on randomization and reported no differences in age, gender, course of the disease, or fasting blood glucose between the two groups. Data from Deng's study[@b36-dddt-12-2827] were inconsistent in terms of wording and should have been proofread by the author. We attempted to contact other authors via email or telephone for more detailed information regarding each trial, but little useful information was received. Considering the limitations of this review, CONSORT statements[@b56-dddt-12-2827] are recommended for the reporting of future clinical trials.

Conclusion
==========

Evidence from this analysis suggests that ALA combined with epalrestat is an efficient therapeutic option for patients with DPN. Future large-sample RCTs should be conducted to verify this finding.

Supplementary materials
=======================

###### 

Represents the search strategy for PubMed, CNKI

  Number                               Search terms
  ------------------------------------ ---------------------------------------------------------------------------------
  **Search strategy used in PubMed**   
  \#1                                  thioctic \[All Fields\]
  \#2                                  acid \[All Fields\]
  \#3                                  \#1 and \#2
  \#4                                  lipoic \[All Fields\]
  \#5                                  acid \[All Fields\]
  \#6                                  \#4 and \#5
  \#7                                  Alpha lipoic acid \[MeSH\]
  \#8                                  Alpha lipoic acid \[TIAB\]
  \#9                                  Alpha lipoic acid \[All Fields\]
  \#10                                 lipoic acid \[MeSH\]
  \#11                                 lipoic acid \[TIAB\]
  \#12                                 lipoic acid \[All Fields\]
  \#13                                 thioctic acid \[MeSH\]
  \#14                                 thioctic acid \[TIAB\]
  \#15                                 thioctic acid \[All Fields\]
  \#16                                 \#3 or \#6 or \#7 or \#8 or \#9 or \#10 or \#11 or \#12 or \#13 or \#14 or \#15
  \#17                                 diabetic \[All Fields\]
  \#18                                 peripheral neuropathy \[All Fields\]
  \#19                                 \#17 and \#18
  \#20                                 neuropathy \[All Fields\]
  \#21                                 \#17 and \#20
  \#22                                 diabetic neuropathy \[All Fields\]
  \#23                                 diabetic peripheral neuropathy \[All Fields\]
  \#24                                 diabetic neuropathy \[MeSH\]
  \#25                                 diabetic peripheral neuropathy \[MeSH\]
  \#26                                 diabetic neuropathy \[TIAB\]
  \#27                                 diabetic peripheral neuropathy \[TIAB\]
  \#28                                 \#19 or \#21 or \#22 or \#23 or \#24 or \#25 or \#26 or \#27
  \#29                                 epalrestat \[MeSH\]
  \#30                                 epalrestat \[Supplementary Concept\]
  \#31                                 epalrestat \[All Fields\]
  \#32                                 epalrestat \[TIAB\]
  \#33                                 \#29 or \#30 or \#31 or \#32
  \#34                                 randomized \[MeSH\]
  \#35                                 randomized controlled trial \[MeSH\]
  \#36                                 randomized controlled trial \[All Fields\]
  \#37                                 randomisation \[MeSH\]
  \#38                                 \#34 or \#35 or \#36 or \#37
  \#39                                 blind \[MeSH\]
  \#40                                 \#16 and \#28 and \#33 and \#38 and \#39
  **Search strategy used in CNKI**     
  \#1                                  diabetes mellitus \[MeSH\]
  \#2                                  peripheral neuropathy \[MeSH\]
  \#3                                  \#1 and \#2
  \#4                                  diabetes mellitus \[Full text\]
  \#5                                  peripheral neuropathy \[Full text\]
  \#6                                  \#4 and \#5
  \#7                                  diabetes mellitus \[key word\]
  \#8                                  peripheral neuropathy \[key word\]
  \#9                                  \#7 and \#8
  \#10                                 diabetic peripheral neuropathy \[MeSH\]
  \#11                                 diabetic peripheral neuropathy \[key word\]
  \#12                                 diabetic peripheral neuropathy \[Full text\]
  \#13                                 \#3 or \#6 or \#9 or \#10 or \#11 or \#12
  \#14                                 lipoic acid \[MeSH\]
  \#15                                 lipoic acid \[key word\]
  \#16                                 lipoic acid \[Full text\]
  \#17                                 lipoic acid capsule \[Full text\]
  \#18                                 lipoic acid injection \[Full text\]
  \#19                                 \#14 or \#15 or \#16 or \#17 or \#18
  \#20                                 epalrestat \[MeSH\]
  \#21                                 epalrestat \[key word\]
  \#22                                 epalrestat \[Full text\]
  \#23                                 \#20 or \#21 or \#22
  \#24                                 \#13 and \#19 and \#23

**Abbreviation:** CNKI, China National Knowledge Infrastructure.

###### 

PRISMA checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **TITLE**                                                                                                                                                                                                                                                                                                                                               
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **ABSTRACT**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   1
  **INTRODUCTION**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                1--2
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    1--2
  **METHODS**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number.                                                                                                                                   2
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                            2
  Information sources                  7    Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                      2--3
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 2--3
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                       2
  Data collection process              10   Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                      3
  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                           3
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        3
  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                                   3
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis.                                                                                                                                                       3
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).                                                                                                                                                                    3
  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                                3
  **RESULTS**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               3--4
  Study characteristics                18   For each study, present characteristics for which data were extracted (eg, study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                    4
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     4--5
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group; 2) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                       4--8
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       4--8
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see item 15).                                                                                                                                                                                                                               4
  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression \[see item 16\]).                                                                                                                                                                                         8
  **DISCUSSION**                                                                                                                                                                                                                                                                                                                                          
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###### 

Characteristics of the included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Year   Age/years EG/CG         Number EG/CG   Intervention methods   Intervention time (days)    Outcomes        
  ----------------------------------- ------ ----------------------- -------------- ---------------------- --------------------------- ---------- ---- -------------------------------------------------------------------------------------------------------------------------------
  He et al[@b31-dddt-12-2827]         2013   82±5/82±5               36/35          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   NCV, clinical effects, adverse reactions, the function of liver and renal, hemanalysis, urinalysis, dynamic electrocardiogram
                                                                                    300 mg, IV qd                                                      

  Fang[@b32-dddt-12-2827]             2014   52.8±12.7/52.8±12.7     30/30          CG + ALA\              Epalrestat 5 mg, PO, tid    14         14   NCV, clinical effects, adverse reactions, the function of liver and renal, FPG, PBG
                                                                                    600 mg, IV qd                                                      

  Liu[@b33-dddt-12-2827]              2014   56.8±5.4/55.2±6.8       24/24          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   NCV, clinical effects
                                                                                    600 mg, IV qd                                                      

  Yan[@b34-dddt-12-2827]              2015   54.8±9.3/54.8±9.3       24/24          CG + ALA\              Epalrestat 50 mg, PO, tid   21         21   NCV, TCSS, TSS
                                                                                    600 mg, IV qd                                                      

  Qu and Zeng[@b35-dddt-12-2827]      2009   58.6±8.7/58.6±8.7       25/25          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   NCV, clinical effects, adverse reactions
                                                                                    600 mg, IV qd                                                      

  Deng[@b36-dddt-12-2827]             2011   45\~72/45--72           43/43          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   NCV, clinical effects
                                                                                    600 mg, IV qd                                                      

  Luo et al[@b37-dddt-12-2827]        2013   57±13/57±13             40/40          CG + ALA\              Epalrestat 50 mg, PO, tid   14         14   NCV, clinical effects
                                                                                    600 mg, IV qd                                                      

  Han[@b38-dddt-12-2827]              2012   63±6/63±5               55/55          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   NCV, clinical effects, adverse reactions, EMG, NSS, MDNS
                                                                                    300 mg, IV qd                                                      

  Wang et al[@b39-dddt-12-2827]       2013   60.1±10.5/57.3±11.2     41/41          CG + ALA\              Epalrestat 50 mg, PO, tid   21         21   NCV, clinical effects, adverse reactions, TCSS, TSS
                                                                                    600 mg, IV qd                                                      

  Yang and Zhang[@b40-dddt-12-2827]   2012   58.3±8.8                50/50          CG + ALA\              Epalrestat 50 mg, PO, tid   28         28   Clinical effects, adverse reactions
                                                                                    600 mg, IV qd                                                      

  Huang[@b41-dddt-12-2827]            2016   54.2±2.7/54.8±2.5       29/29          CG + ALA\              Epalrestat 50 mg, PO, tid   21         21   NCV, clinical effects, adverse reactions, TCSS, TSS
                                                                                    600 mg, IV qd                                                      

  Qi[@b42-dddt-12-2827]               2016   58.01±7.73/57.31±6.79   30/30          CG + ALA\              Epalrestat 50 mg, PO, tid   21         21   NCV, clinical effects
                                                                                    600 mg, IV qd                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** EG (experimental group), the group administered lipoic acid combined with epalrestat; CG (control group), the group administered lipoic acid monotherapy; ALA, α-lipoic acid; qd, once a day; IV, intravenous injection; PO, oral administration; tid, three times a day; NCV, nerve conduction velocity; EMG, electromyography; TCSS, Toronto Clinical Scoring System; TSS, Total Symptom Score; NSS, Neurological Symptom Score; MDNS, Michigan Diabetic Neuropathy Score; FPG, fasting plasma glucose; PBG, postprandial blood glucose.

###### 

Meta-analysis of ALA combined with epalrestat vs epalrestat monotherapy

  Treatment strategy                                                                                      Follow-up time (days)                                                              Studies numbers                                                Number EG/CG   Heterogeneity   Model    WMD (95% Cl)         *Z*                    *P*-value   Difference between groups           
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------- -------------- --------------- -------- -------------------- ---------------------- ----------- --------------------------- ------- ---------
  **Median MNCV**                                                                                                                                                                                                                                                                                                                                                                               
  ALA 600 mg/d qd combined with epalrestat 50 mg tid ALA 300 mg/d qd combined with epalrestat 50 mg tid   14                                                                                 2[@b32-dddt-12-2827],[@b37-dddt-12-2827]                       70/70          0               0.97     Fixed                7.98 (6.17, 9.80)      8.63        0.00001                     24.41   0.00001
  21                                                                                                      3[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b42-dddt-12-2827]                       95/95                                                          70             0.03            Random   2.74 (1.50, 3.98)    4.33                   0.0001                                          
  28                                                                                                      3[@b33-dddt-12-2827],[@b35-dddt-12-2827],[@b36-dddt-12-2827]                       92/92                                                          98             0.00001         Random   9.01 (3.46, 14.56)   3.18                   0.001                                           
  28                                                                                                      2[@b31-dddt-12-2827],[@b38-dddt-12-2827]                                           90/90                                                          0              0.79            Fixed    6.12 (5.04, 7.20)    11.12                  0.00001     NA                          NA      
  **Peroneal MNCV**                                                                                                                                                                                                                                                                                                                                                                             
  ALA 600 mg/d qd combined with epalrestat 50 mg tid ALA 300 mg/d qd combined with epalrestat 50 mg tid   14                                                                                 2[@b32-dddt-12-2827],[@b37-dddt-12-2827]                       70/70          0               0.62     Fixed                9.77 (7.78, 11.75)     9.64        0.00001                     10.84   0.004
  21                                                                                                      4[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b41-dddt-12-2827],[@b42-dddt-12-2827]   124/124                                                        93             0.00001         Random   4.18 (1.49, 6.88)    3.05                   0.002                                           
  28                                                                                                      3[@b33-dddt-12-2827],[@b35-dddt-12-2827],[@b36-dddt-12-2827]                       92/92                                                          96             0.00001         Random   7.13 (3.94, 10.32)   4.38                   0.0001                                          
  28                                                                                                      2[@b31-dddt-12-2827],[@b38-dddt-12-2827]                                           90/90                                                          0              0.74            Fixed    6.68 (5.82, 7.55)    15.16                  0.00001     NA                          NA      
  **Median SNCV**                                                                                                                                                                                                                                                                                                                                                                               
  ALA 600 mg/d qd combined with epalrestat 50 mg tid ALA 300 mg/d qd combined with epalrestat 50 mg tid   14                                                                                 2[@b32-dddt-12-2827],[@b37-dddt-12-2827]                       70/70          0               0.79     Fixed                7.12 (5.13, 9.11)      7.02        0.00001                     10.51   0.005
  21                                                                                                      3[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b42-dddt-12-2827]                       95/95                                                          0              0.77            Fixed    3.88 (3.08, 4.68)    9.54                   0.00001                                         
  28                                                                                                      3[@b33-dddt-12-2827],[@b35-dddt-12-2827],[@b36-dddt-12-2827]                       92/92                                                          99             0.00001         Random   9.97 (1.56, 18.38)   2.23                   0.02                                            
  28                                                                                                      2[@b31-dddt-12-2827],[@b38-dddt-12-2827]                                           90/90                                                          0              1.00            Fixed    6.70 (5.75, 7.65)    13.88                  0.00001     NA                          NA      
  **Peroneal SNCV**                                                                                                                                                                                                                                                                                                                                                                             
  ALA 600 mg/d qd combined with epalrestat 50 mg tid ALA 300 mg/d qd combined with epalrestat 50 mg tid   14                                                                                 2[@b32-dddt-12-2827],[@b37-dddt-12-2827]                       70/70          0               0.61     Fixed                7.76 (5.77, 9.76)      7.62        0.00001                     6.34    0.04
  21                                                                                                      4[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b41-dddt-12-2827],[@b42-dddt-12-2827]   124/124                                                        90             0.00001         Random   3.30 (0.45, 6.14)    2.27                   0.02                                            
  28                                                                                                      3[@b33-dddt-12-2827],[@b35-dddt-12-2827],[@b36-dddt-12-2827]                       92/92                                                          97             0.00001         Random   6.29 (3.01, 9.58)    3.76                   0.0002                                          
  28                                                                                                      2[@b31-dddt-12-2827],[@b38-dddt-12-2827]                                           90/90                                                          0              0.75            Fixed    4.27 (3.34, 5.20)    8.97                   0.00001     NA                          NA      
  **TCSS**                                                                                                                                                                                                                                                                                                                                                                                      
  ALA 600 mg/d qd combined with epalrestat 50 mg tid                                                      21                                                                                 3[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b41-dddt-12-2827]   94/94          80              0.006    Random               −1.60 (−2.91, −0.29)   2.39        0.02                        NA      NA
  **TSS**                                                                                                                                                                                                                                                                                                                                                                                       
  ALA 600 mg/d qd combined with epalrestat 50 mg tid                                                      21                                                                                 3[@b34-dddt-12-2827],[@b39-dddt-12-2827],[@b41-dddt-12-2827]   94/94          0               0.69     Fixed                −0.93 (−1.27, −0.60)   5.43        0.00001                     NA      NA

**Abbreviations:** EG (experimental group), the group administered lipoic acid combined with epalrestat; CG (control group), the group administered lipoic acid monotherapy; ALA, α-lipoic acid; WMD, weighted mean difference; MNCV, median motor nerve conduction velocity; SNCV, median sensory nerve conduction velocity; NA, not available; TCSS, Toronto Clinical Scoring System; TSS, Total Symptom Score.

###### 

Sensitivity analysis of median MNCV and SNCV

  Treatment strategy                                   Follow-up time (days)   Eliminate study          Studies numbers                            Numbers EG/CG   Heterogeneity   Model   WMD (95% Cl)   *Z*                 *P*-value   
  ---------------------------------------------------- ----------------------- ------------------------ ------------------------------------------ --------------- --------------- ------- -------------- ------------------- ----------- ---------
  **Median MNCV**                                                                                                                                                                                                                         
  ALA 600 mg/d qd combined with epalrestat 50 mg tid   28                      Liu[@b33-dddt-12-2827]   2[@b35-dddt-12-2827],[@b36-dddt-12-2827]   68/68           17              0.27    Fixed          6.64 (5.52, 7.36)   13.74       0.00001
  **Median SNCV**                                                                                                                                                                                                                         
  ALA 600 mg/d qd combined with epalrestat 50 mg tid   28                      Liu[@b33-dddt-12-2827]   2[@b35-dddt-12-2827],[@b36-dddt-12-2827]   68/68           34              0.22    Fixed          5.72 (4.98, 6.47)   15.06       0.00001

**Abbreviations:** EG (experimental group), the group administered lipoic acid combined with epalrestat; CG (control group), the group administered lipoic acid monotherapy; ALA, α-lipoic acid; WMD, weighted mean difference; MNCV, median motor nerve conduction velocity; SNCV, median sensory nerve conduction velocity.
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